Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open-label, non-controlled, multicenter, multinational Study to evaluate the Efficacy and Safety of Zemaira administration in Chronic Augmentation and Maintenance Therapy in Subjects with Emphysema due to Alpha1-Proteinase Inhibitor Deficiency who completed Clinical Study CE1226_4001

Next Previous
Trial Profile

An open-label, non-controlled, multicenter, multinational Study to evaluate the Efficacy and Safety of Zemaira administration in Chronic Augmentation and Maintenance Therapy in Subjects with Emphysema due to Alpha1-Proteinase Inhibitor Deficiency who completed Clinical Study CE1226_4001

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 21 Sep 2018

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Alpha 1-antitrypsin (Primary)
  • Indications Emphysema
  • Focus Therapeutic Use
  • Acronyms RAPID Extension trial
  • Sponsors CSL Behring

Most Recent Events

  • 13 Sep 2018 According to a CSL Behring media release, results of the subgroup analysis of the RAPID trial programme will be presented at the 28th International Congress of the European Respiratory Society (ERS).
  • 24 May 2017 Results Post-Hoc Analysis of the RAPID/RAPID Extension Trialpresented at the 113th International Conference of the American Thoracic Society
  • 02 Dec 2016 Data from this trial published in the Lancet Respiratory Medicine, as per a CSL Behring media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top